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Abstract
Background: Loss-of-function in the apoptosis-inducing genes is known to facilitate tumorigenesis. AFX (FOXO4), a member
of forkhead transcription factors functions as a tumor suppressor and has 2 isoforms, AFXa (505 a.a.) and AFXf (450 a.a.). In
human cancer cells, we identified an N-terminally deleted form of AFXa (a198-505), translated from a downstream start and
2 short N-terminal AFX proteins (90, and 101 a.a.) produced by aberrant splicing.
Methods and Findings: We investigated the expression and role of these AFX variants. Cell transduction study revealed that
short N-terminal AFX proteins were not stable. Though a(198-505) protein expression was detected in the cytoplasm and
nucleus, a(198-505) expressing cells did not show a nucleocytoplasmic shuttling mediated by PI3 kinase signaling. Whereas,
we observed this shuttling in cells expressing either AFXa or AFXf protein. AFXf and a(198-505) lost the ability to
transactivate BCL6 or suppress cyclin D2 gene expression. These variants did not induce cancer cell death whereas AFXa
resulted in apoptosis. We found that AFXf and a(198-505) suppress the AFXa stimulation of BCL6 promoter in a dose
dependent manner, indicating dominant negative activity. These variants also inhibited AFXa induction of apoptosis.
Conclusions: Loss of function by aberrant splicing and the dominant negative activity of AFX variants may provide a
mechanism for enhanced survival of neoplastic cells.
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Introduction
AFX (FOXO4) is a member of the class O (FOXO) subfamily of
forkhead transcription factors that includes the functionally related
proteins FOXO1 (FKHR), FOXO3a (FKHRL1), and FOXO4
[1,2]. FOXO transcription factors have important roles in metab-
olism, cellular proliferation, and apoptosis. Overproduction of
FOXOs induces either cell cycle arrest or apoptosis. When relieved
of FOXO activity, cells re-enter the cell cycle and start to proliferate
[3]. A role for FOXO members in tumorigenesis was initially
suggested by the observation that FOXO members are involved
chromosomal translocations in certain types of tumors [4,5]. The
PAX3-FKHR fusion product has been shown to transform cells in
culture [6]. However, translocations involving FOXO proteins might
also result in loss-of-function of a FOXO allele.
AFX is known to have two isoforms, AFXa (505 amino acids)
and AFXf (450 amino acids) [7]. AFXf is a splice variant that
encodes a shorter protein lacking amino acids 58-112, including
the first 16 amino acids of the forkhead domain. AFXa is
ubiquitously expressed, whereas AFXf is expressed predominantly
in liver, kidney, pancreas, heart, and placenta. AFXf transcripts
are not detected in ovary, testis, brain, prostate, colon, and
leukocyte. The different tissue distributions AFXa and AFXf
suggest distinct transcriptional regulation and actions on a
different subset of target genes.
In this report, we describe novel spliced forms of the AFX
transcript in human cancer cells and their effect on tumor
apoptosis and growth.
Results
AFX splicing variants
PCR amplification of reverse-transcribed cDNA samples from
human cancer cell lines was performed using a primer set that
anneals to both AFXa and AFXf cDNAs. The upper band (445
bp) corresponds to AFXa and lower band (290 bp) contains AFXf.
There was a slight difference in the size of AFXf bands among the
cell lines, prompting us to consider possible splicing variants
(Fig. 1A). Direct sequencing of lower bands identified the AFXf
isoform, as well as overlapping and mixed sequences near splice
acceptor site of AFXf isoform (not shown). The lower bands were
cloned and sequenced to investigate these sequences further. Two
novel splicing variants were identified, in which the splice
acceptance occurred aberrantly at 4 and 14 bases before splice
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splicing results in either a 4 or 14 base insertion, leading to a shift
of the reading frame and producing premature stop codon.
Splicing variants with the 4 or 14 base insertion encode predicted
proteins of 90 (AFXtr1) or 101 (AFXtr2) amino acids, respectively
(Fig. 1C). A variety of tumor cells showed different patterns of
AFX transcripts (Fig. 1A). Either AFXtr1 or AFXtr2 were detected
in most tumor cells. AFXf was detected in DOV13, OVCA429,
CaCO2, HEK293, and 293FT cells. AFXa expression was absent
in OVCA429 and 293FT cells. JEG3 cells express only AFXa.
Percent ratio of AFXf, AFXtr1, and AFXtr2 was different each
other according to tumor cells (Fig. 1A).
We became interested in the N-terminally truncated AFXa
proteins because AFXtr1 and AFXtr2 are prematurely terminated
in exon 1, and three potential alternative start codons (M1, M2,
and M3) are present in exon 1b and 2 (Fig. 2A). M3 is the
methionine codon located at the end of forkhead domain. It
contains a consensus Kozak sequence for initiation of translation
and thus potentially encodes an N-terminally deleted AFXa.
Western blot analyses using an anti-HA antibody from the lysate
of 293FT cells transfected with C-terminal hemaglutinin (HA)
epitope-tagged AFXa detected an additional band, suggesting a
presence of N-terminally deleted AFX protein (Fig. 2B, arrow). In
order to identify this product, we generated three N-terminally
deleted AFX constructs tagged with C-terminal-HA epitope
{a(131-505)-HA, a(178-505)-HA, and a(198-505)-HA}. Western
blotting with anti-AFX antibody (C-terminal specific) after
immunoprecipitation with anti-HA antibody of transfected cell
lysates confirmed the presence of the a(198-505) protein (Fig. 2C,
arrow).
Figure 1. AFX splicing variants. (A) RT-PCR of total RNA samples from human cancer cell lines. The upper band (445 bp) represents AFXa and the
lower band (290 bp) contains AFXf. Lower bands were cloned and sequenced. Percent ratio of AFXf, AFXtr1, and AFXtr2 was calculated. 1-12,
Sequencing results of cloned lower bands from each cell line (a, AFXa; f, AFXf; tr1, AFXtr1; and tr2, AFXtr2); 13, AFXa cDNA; and 14, AFXf cDNA. (B, C)
Schematic representation of AFXa and AFXf, and AFX splicing variants by aberrant splicing. The splice acceptance occurred aberrantly at 4 (b) and 14
(c) bases before splice acceptor site (a) of AFXf isoform. This aberrant splicing results in 4 and 14 base insertions, leading to a shift of reading frame
and producing premature stop codon. Splicing variants with 4 and 14 bases insertion have 90 (AFXtr1) and 101 (AFXtr2) amino acids (a.a.),
respectively.
doi:10.1371/journal.pone.0002743.g001
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Cellular protein processing and localization of AFX variants
was examined by immunofluorescence (IF) staining. JEG3 cells
were transfected with the constructs carrying the N- or C-terminal
HA epitope in-frame with AFXa-HA, AFXf-HA, or a(198-505)-
HA. Immunofluorescence positivity was detected in about 5–8%
of JEG3 cells. No protein expression was detected in cells
transfected with HA-AFXtr1 and HA-AFXtr2 (Data not shown).
To achieve high levels of gene expression, we generated adenoviral
vectors carrying these constructs. After determining the dose of
adenoviral vectors required to achieve 95–100% expression of the
control b-galactosidase gene in HeLa cells, protein expression was
still not detected for vectors containing HA-AFXtr1 or HA-
AFXtr2 (data not shown), whereas 90–95% of cells expressed
AFXa-HA, AFXf-HA, or a(198-505)-HA in either cytoplasms
and nuclei (Fig. 3A). These results indicate that the short
aminoterminal-AFX proteins are not appropriately processed or
stable in the cells, although the product from the alternate
translation start site a(198-505) is produced.
The effect of the cell signaling on subcellular localization was
assessed by adding insulin, EGF, or LY294002 (a PI3 kinase
inhibitor). Insulin and EGF treatment induced the excursions of
AFXa and AFXf to cytoplasms and LY294002 pretreatment
prevented these excursions, indicating that nucleocytoplasmic
shuttling of AFXa or AFXf protein is occurred and regulated by
PI3 kinase signaling pathway. Whereas a(198-505) expressing cells
did not show this shuttling (Fig. 3B). This defect may be due to the
fact that a(198-505) has lost two binding sites for 14-3-3 protein
and half of the nuclear localization sequence (182-211 amino
acids) [8,9,10,11].
AFX variants fail to transactivate the BCL6 gene or
suppress the cyclin D2 gene
The transcriptional activity of AFXf and a(198-505) was
compared to AFXa usinga luciferase reporter system. The amounts
of plasmid vectors transfected were carefully optimized to minimize
nonspecific effects [12] and luciferase values were normalized by
protein measurements. AFXf and a(198-505) did not stimulate
3IRS-TATA-Luc, whereas AFXa activated this reporter about 15-
fold (Fig. 4A). Two representative target genes, BCL6 and cyclin
D2, were also examined. BCL6 is a transcriptional repressor of
BCL-XL, an antiapoptotic protein, and the AFX protein is thought
to induce activates apoptosis by stimulation of BCL6 [13]. The cell
cycle inhibition by AFX protein involves down-regulation of cyclin
D [14]. In 293FT cells, AFXf and a(198-505) did not stimulate
BCL6p-Luc or suppress CD2p-Luc, whereas AFXa stimulated
BCL6p-Luc 13-fold and suppressedCD2p-Luc by75% (Fig.4B,C).
RT-PCR and Western blot analyses were used to investigate the
effectofthe AFXvariantsonthe expression ofBCL6 orcyclinD2in
cells infected with adenoviral vectors carrying AFXa,A F X f,o r
a(198-505). Whereas AFXa induced BCL6 expression in MCF7
cells, Ad-f or Ad-a(198-505) did not increase either BCL6 mRNA
orprotein(Fig.4D). Ad-a suppressed cyclinD2expression,however
Ad-f or Ad-a(198-505) lost the ability to suppress its expression in
MCF7 or OVCA429 cells (Fig. 4E). These results indicate that the
AFX variants are loss-of-function mutants.
AFX variants have lost the ability to suppress tumor cell
growth
HepG2, T47D, HeLa, OVCA429, and OVCA420 cells were
infected with adenoviral vectors (from 2.5 to 10 PFU/cell )
!
Figure 2. Identification of N-terminally deleted AFX protein, a(198-505). (A) Three start codons (M1, M2, and M3) are present in exon 1b and
2. M3 is the methionine codon located at the end of forkhead domain, which contains a consensus Kozak sequence for initiation of translation. (B)
Western blot analysis. We detected an additional band (arrow) using anti-HA antibody from the lysate of 293-FT cells transfected with AFXa-HA (C-
terminal tagged), suggesting a presence of N-terminally deleted AFX protein. (C) Immunoprecipitation analysis. To identify truncated protein, three
N-terminally deleted AFX constructs tagged with C-terminal-HA epitope {a(131-505)HA, a(178-505)HA, and a(198-505)HA} were transfected. Western
blotting with anti-AFX antibody (C-terminal specific) after immunoprecipitation with anti-HA antibody of transfected cell lysates revealed a(198-505)
protein (arrow).
doi:10.1371/journal.pone.0002743.g002
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using the MTS assay at day 6 and the percent cell survival was
calculated compared to Ad-Empty (Ad-E) infection. Infection of
Ad-a suppressed 70–95% cell growth, whereas Ad-f or Ad-a(198-
505) did not suppress cell growth (Fig. 5A), indicating that the
AFX variants have lost the ability to suppress tumor cell growth.
AFX variants inhibited AFXa induction of cell death by a
dominant negative effect on the BCL6 gene
We examined whether AFX variants might inhibit AFXa
induction of apoptosis through dominant negative activity. An
additional adenoviral vector {Ad-a(1-200)} were constructed
containing AFXa(1-200), a C-terminal truncation mutant that
contains a functional DNA-binding domain, but lacks a transacti-
vation domain. A similar FOXO1(1-255) construct has been
shown to have dominant negative activity [15,16]. Ad-a(1-200)
infection alone did not induce cell death in HepG2, T47D, HeLa,
OVCA429, and OVCA420 cells (data not shown). Co-infection of
Ad-a with equal (5 PFU/cell) or higher (15 PFU/cell) amounts of
Ad-E, Ad-f, Ad-a(198-505), or Ad-a(1-200) in T47D cells were
performed to investigate the effect of AFX variants on AFXa
induction of apoptosis. Because high amounts of adenoviral vector
alone induce cell death, control infections were performed using
Figure 3. Expression and subcellular localization of AFX variants. HeLa cells were seeded on fibronectin coated cover glass and infected with
adenoviral vectors carrying C-terminal HA-epitope tagged AFXs. Immunofluorescence staining using anti-HA antibody was performed. (A) Not
treated. (B) Treated with insulin, EGF, LY294002, and LY294002 followed by EGF. a, AFXa; and f, AFXf.
doi:10.1371/journal.pone.0002743.g003
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amount of co-infected adenoviral vectors. Co-infection of Ad-a
and Ad-E induced 30–40% more cell death compared to
corresponding amounts of Ad-E infection. Co-infection of Ad-f,
Ad-a(198-505), or Ad-a(1-200) prevented AFXa induction of cell
death (Fig. 5B), suggesting dominant negative activity of AFX
variants. Cellular examination was also performed using double
immunofluorescent. HeLa cells expressing nucleic AFXa alone
showed apoptotic nuclei, whereas HeLa cells co-expressing AFXa
with AFXf or a(198-505) did not show apoptosis. Of note, AFXa
was co-localized with AFXf or a(198-505) in nuclear speckles of
these cells (Fig. 5C).
The mechanism of dominant negative activity of AFX variants
was assessed further by examining effects on transcriptional
regulation of 3IRS-TATA-Luc, BCL6p-Luc, and CD2p-Luc.
Co-transfection of AFXa with equal or increasing amounts of the
AFX variants was preformed in the context of these luciferase
reporters. Co-transfection with the AFX variants reduced the
AFXa-induced transactivation of 3IRS-TATA-Luc and BCL6p-
Luc in a dose-dependent manner (Fig. 6A, B). The reduction by
AFXf was comparable to that of a(1-200). However, the AFX
variants did not reverse AFXa suppression of CD2p-Luc activity
(Fig. 6C). These results suggest that the inhibition of AFXa-
induced apoptosis is mediated through dominant negative activity
of AFX variants on AFXa in BCL6 gene expression.
Discussion
In this report, we identified spliced forms of AFX transcripts
in multiple human cancer cell lines. Short aminoterminal AFX
proteins (AFXtr1 and AFXtr2) produced by aberrant splicing
were not stable, suggesting AFX inactivation by aberrant
splicing. However, alternative splicing and translation produced
AFXf and a(198-505), respectively. AFXf and a(198-505) lost
the ability to transactivate BCL6 or to suppress cyclin D2 gene
expression. Although inactive as individual transcription factors,
Figure 4. AFX variants do not transactivate the BCL6 gene or suppress the cyclin D2 gene. (A, B, C) Transcriptional activity of AFXf and
a(198-505) compared to AFXa using a luciferase reporter system. 293-FT cells were co-transfected with AFX expression vectors and luciferase reporter
constructs, 3IRS-TATA-Luc (A); BCL6p-Luc (B); and CD2p-Luc (C). Luciferase values were normalized by protein measurements. Results were averaged
from 3 independent experiments and are plotted as means6standard deviations for quadruplicated wells. (D) RT-PCR and Western blot analysis of
BCL6 expression in MCF7 cells infected with Ad-E, Ad-a, Ad-f or Ad-a(198-505). (E). Western blot analysis of cyclin D2 expression in MCF7 and
OVCA429 cells infected with Ad-E, Ad-a, Ad-f or Ad-a(198-505).
doi:10.1371/journal.pone.0002743.g004
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Figure 5. AFX variants do not suppress tumor cell growth. (A) Cell survival after transduction of AFXa, AFXf, and a(198-505). HepG2, T47D,
HeLa, OVCA429, and OVCA420 cells were infected with adenoviral vectors from 2.5 to 10 PFU/cell and cell viability was assessed using the MTS assay
at day 6. The amount of adenoviral vectors for each cell line was optimized to achieve 95–100% expression levels. Percent cell survival was calculated
compared to Ad-E infection. (B) AFXf and a(198-505) inhibits AFXa induced growth suppression. We used an adenoviral vector {Ad-a(1-200)}
containing AFXa(1-200), a C-terminal truncation mutant that has dominant negative activity. Four days after co-infection of adenoviral vectors, cell
viability was assayed. Results were averaged from 3 independent experiments and are plotted as means6standard deviations for quadruplicated
wells. (C) Prevention of Ad-a induced apoptosis by Ad-f and Ad-a(198-505). Double immunofluorescent staining was performed to identify cells
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AFXa stimulation of BCL6 gene. These variants also lost the
ability to induce apoptosis but they inhibited AFXa induced
apoptosis, presumably through dominant negative activity on
the BCL6 gene. Inactivation of AFX by aberrant splicing and
the dominant negative function of the AFX splicing variants
could therefore provide a growth advantage during cancer
progression.
 
Figure 6. AFX variants exert dominant negative activity on the BCL6 gene promoter. (A, B, C) Co-transfection of AFXa with equal or
increasing amounts of the AFX variants was performed in the context of the luciferase reporters, 3IRS-TATA-Luc (A), BCL6p-Luc (B) and CD2p-Luc (C).
The a(1-200) construct was used as a known dominant negative mutant. Results were averaged from 3 independent experiments and are plotted as
means6standard deviations for quadruplicated well. E, Empty; a, AFXa; and f, AFXf.
doi:10.1371/journal.pone.0002743.g006
infected with two viruses. HeLa cells infected with Ad-a showed apoptotic nuclei (arrow), whereas HeLa cells co-infected with either Ad-f or Ad-
a(198-505) did not show apoptosis. Anti-AFX(N), N-terminal specific antibody against AFX; E, Ad-E, a; Ad-a; f, Ad-f ; f-HA, Ad-f-HA; and a(198-505),
Ad-a(198-505).
doi:10.1371/journal.pone.0002743.g005
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each other because of their distinct transcriptional activity for
different target genes. For example, AFXf stimulates PEPCK,
G6Pase promoters, whereas AFXa does not activate these
promoters [7]. We also observed distinct transcriptional regulatory
function for AFXa and AFXf. The CD2 promoter was weakly
stimulated by AFXf and repressed by AFXa (Fig. 4C). A novel
finding in this study is the dominant negative function of AFXf or
a(198-505) on AFXa regulation of the BCL6 promoter. A number
of AFXa binding sites have been demonstrated in BCL6 promoter
[13]. One AFXa binding site was also competed by a known
forkhead-binding site (IRS) derived from the IGFBP-1 promoter
[13]. Consistent with this, we also observed dominant negative
activity by the AFX variants on AFXa stimulation of 3xIRS
promoter construct. These results indicate that the dominant
negative activity by AFX variants may be mediated through IRS
(GCAAAACAA AC TTATTTTGAA).
The induction of BCL6 accounts for part of the apoptotic
mechanism mediated by AFXa. FOXO dependent expression of
IGFBP-1 [17], FasL [18,19] and Bim [20–23] have also been
shown to promote apoptosis. Direct FOXO binding activity has
been demonstrated in the FasL promoter (GTAAATAAATA) and
the Bim promoter (GTAAACAC). It is possible that the AFX
variants may also influence AFXa activation of these genes.
Of note, the AFX variants did not reverse AFXa suppression of
the CD2 promoter. FOXO factors have been shown to elevate
p27KIP1 expression and induce cell cycle arrest [24,25].
FOXO3a and AFX have also been shown to inhibit the cell cycle
through downregulation of cyclin D by a p27KIP1-independent
mechanism [2,14,26]. Chromatin immunopreciptation (ChIP)
using the cyclin D1 [27] and cyclin D2 promoters [28]
demonstrated FOXO binding on the cyclin D promoters.
However, a recent study suggested that transcriptional repression
of D-type cyclin may not involve direct binding of FOXO factors
to cyclin D1 or D2 promoters [26]. These results suggest that
transcription repressors activated by AFXa might play a role in
downregulation of cyclin D.
An important question is whether there is a causal relationship
between AFX splicing variants and cancer. For this to be feasible,
the alternative splicing products would need to be expressed at
significant levels compared with the normally spliced product [29].
We compared the pattern of AFX transcripts in two different cell
lines (HEK 293 and 293FT) originated from same cells. By RT-
PCR there was a decrease of the AFXa transcript in 293FT cells,
whereas HEK293 cells still possessed it (Fig. 1A). HEK293 cells
are transformed by the adenovirus E1 gene and 293FT cells were
additionally transformed by simian virus (SV) 40 large tumor
antigen. Loss of the AFXa transcript and the appearance of the
AFX variants could contribute to the higher proliferation of
293FT cells relative to HEK293 cells (data not shown). However,
the mechanism described in our study remains to be determined in
primary tumors.
Defects in mRNA splicing occur frequently in human cancer
cells [29] but the mechanisms leading to splicing defects in cancer
are poorly understood. A point mutation in the genomic splice site
or regulatory elements have been shown in selected splicing defects
[30–32]. However, DNA sequencing of the intronic and exonic
portions of AFX gene did not reveal mutations. Variations in the
composition, concentration, localization, and activity of transact-
ing regulatory factors may also modulate splice-site recognition
and usage [33,34]. Activation of the oncogenic signal pathway also
stimulates aberrant splicing [35]. It is of interest to better
understand how splicing regulatory factors in cancer cells might
affect AFX aberrant splicing and thereby cell survival.
Methods
Cells and culture
Cell lines for ovarian cancer (DOV13, OVCA420, OVCA429,
and OVCA433), colon cancer (DLD1, CaCO2), breast cancer
(MCF7, T47D), choriocarcinoma (JEG3), hepatoma (HepG2),
cervical cancer (HeLa), and transformed human embryonic kidney
cells (HEK293, and 293FT) were cultured in DMEM/F12
supplemented with 10% fetal bovine serum (FBS), 100 units/ml
penicillin, and 100 mg/ml streptomycin. All cells were maintained
at 37uC with 5% CO2.
RT-PCR and sequence analysis
Total RNA was extractedfrom each cells using TRIZOL reagent
(Invitrogen, Carlsbad, CA) as described by the manufacturer. RNA
(20 mg) was treated with DNAse-I (Promega, Madison, WI) for
30 min at room temperature. Random hexamers and AMV reverse
transcriptase (RT) were used to synthesize cDNA using 10 mgo f
DNAse-I treated RNA. A portion (1/40) of the cDNA solution was
used for amplification of AFX. Cycle conditions were: 2 min hot
start at 96uC, followed by 35 cycles of 1 min at 94uC, 45 sec at
56uC, followed by 1 min at 72uC, and a final extension at 72uC for
5 minutes. An aliquot (50%) of each PCR reaction was resolved by
electrophoresis on 1.8% agarose gels and DNA products were
visualized with ethidium bromide. Oligonucleotides used for PCR
amplification include forward 59-ACG TAT GGA TCC GGG
GAA TG-39 and reverse 59-TCC ATC CTG CTG AGC TGT-39.
PCR product give two bands; AFXa (445 bp) and AFXf (290 bp).
The lower AFXf bands were excised and cloned into p-TOPO
vector (Invitrogen). To identify splicing variants, 20 positive clones
carrying the PCR segment from each cell line were sequenced using
an automated DNA sequencer.
Plasmids and transfections
The cDNAs for AFXa, AFXf, AFXa(198-505), AFXa(1-200),
AFXtr1, and AFXtr2 were amplified using KOD DNA polymer-
ase (Novagen, San Diego CA) and the RT product of total RNAs
from cancer cells and cloned into pCRH-Blunt (Invitrogen). After
verification of sequencing, each cDNA was subcloned into
pCDNA3. Fusion constructs were created by incorporating an
N- or C-terminal influenza virus HA epitope (YPYDVPDYA) in-
frame with the AFXs in the pCDNA3 vectors.
In a preliminary transfection study using the pGL3 basic vector
(Promega, Madision WI), we observed that AFXa stimulated
luciferase activity about 60-fold. We found 2 IRS-A (CAAAA-
CAA) sequences in the synthetic polyA (spA) region and removed
them (NotI and KpnI). After confirmation that neither AFXa or
AFXf stimulated spA deleted pGL3basic vector, the sequences
containing 36insulin response sequences (IRSs, GCAAAACAA
AC TTATTTTGAA) [36] and TATA box, the human BCL6
promoter (2785 +55) [13], and the human cyclin D2 promoter
(1302 bps) [14] were inserted into multiple cloning sites to generate
3IRS-TATA-Luc, BCL6p-Luc, and CD2p-luc, respectively.
Transfections of 293FT cells with 500 ng of luciferase constructs
and 10 ng of each AFX construct were performed using the
calcium phosphate method. Forty eight hrs later, cells were
harvested 48h later and luciferase activity was assayed and
normalized as described before [12]. Results were averaged from 3
independent experiments and are plotted as means6standard
deviations for quadruplicated wells.
Adenoviral infection and cell proliferation assay
Recombinant adenoviral vectors {Ad-a, Ad-aHA, Ad-f, Ad-
fHA, Ad-a(198-505), Ad-a(198-505)HA, and Ad-a(1-200)} carry-
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amplified, purified, titrated as described previously [37]. Cytotox-
icity was assessed using a nonradioactive cell proliferation assay
according to the manufacturer’s protocol (Cell Titer 96 Aqueous
Non-Radioactive Cell Proliferation Assay, Promega). The day
after plating 3610
3 cells per well in 96-well plates, adenoviral
vectors {Ad-a, Ad-f, and Ad-a(198-505)} were infected at various
MOIs (2.5-10 plaque forming unit/cell). Empty adenoviral vector
(Ad-E) was also infected as a control. To achieve 100% cellular
expression of adenoviral transgene, MOIs for each cell line were
determined by infection of an adenovirus carrying b-galactosidase
[37]. Fresh medium (DMEM/F12 supplemented with 2.5% heat
inactivated FBS) was added 8 h after infection and every 2 days
thereafter. Cell viability was assayed 6 days after infection. Percent
cell survival was quantitated relative to Ad-E infected or
uninfected cells.
Immunofluorescence
Transfected or infected cells were reseeded on cover glasses
precoated with fibronectin. Twenty four hrs later, cells were fixed
in cold methanol for 10 min and permeabilized in 0.4% Triton-
X/PBS for 10 min. After washing with TBS/0.05% Tween, rat
monoclonal anti-HA high affinity antibody (Clone 3F10, 2.5 mg/
ml, Roche Diagnostic Co, Manm, Germany) was incubated for 2
hrs. Visualization was performed using anti-rat Ig-biotin, F(ab’)2
fragment (5 mg/ml, Jackson Immunoresearch, city) and streptavi-
din-Texas Red (1:100, Vector Laboratories Inc., Burlingame, CA).
Cell images were analyzed using a Zeiss microscope (Axioskop,
Carl Zeiss Inc., Oberkochen, Germany). For N-terminal specific
antibody against AFX (Goat, AFX-N, Santa Cruz Biotechnology,
Inc. Santa Cruz CA), biotinylated anti-goat antibody (1:300,
Vector lab) was used. Each antibody was optimized and titrated to
minimize nonspecific activity.
Immunoprecipitation and Western blot analysis
Immunoprecipitation and Western blot analysis using lysates
from cells were performed as described previously [16,38].
Primary antibodies used were anti-HA high affinity antibody
(Roche), anti-AFX antibody (C-terminal specific, A-8975, Sigma-
Aldrich, Inc. Saint Louis MO), anti-BCL6 (N-3, Santa Cruz
Biotechnology) and anti-cyclin D2 (M-20, Santa Cruz Biotech-
nology).
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